BioTaiwan 2015, one of the largest bio-gatherings in Asia, took place in Taipei World Trade Center Nangang Exhibition Hall from July 23rd to July 26th. During the exhibit, Medigen Vaccine Biologics Co. (MVC) hosted activities to share our recent accomplishment in influenza and enterovirus vaccine development. The exterior construction of vaccine plant for MVC, located in Hsinchu Biomedical Park, is completed, and the interior installation is ongoing. PIC/s GMP-certification of MVC’s plant and pilot production are expected to begin next year.
1. BioBusiness Asia 2015
MVC invited scientists and vaccine experts from The Netherlands, Denmark, Japan and Korea to discuss topics including: opportunities in development of vaccines, manufacturing, GMP regulation and new route of vaccine administration. Hopefully through in-depth discussions we can build a roadmap for a successful vaccine industry in Taiwan.
2. Workshop: Introduction to Enterovirus
MVC endeavors to provide not only high quality vaccine product, but latest healthcare information to the public. By delivering accurate healthcare knowledge to the public, we can integrate the power of industries and the public to protect children from infection diseases.
1: Section topic: Roadmap for a successful biologics business. From left to right: Dr. Hsu-Sung Kuo, Director General of Taiwan Centers for Disease Control (Taiwan CDC). Dr. Li-Min Huang, director of pediatric infectious disease department in Taiwan University Hospital. Dr. Masato Tashiro, former director of WHO Collaborating Centre for Reference and Research on Influenza. Dr. Chung Keel Lee, special advisor to minister of Korea Ministry of Food and Drug Safety. Sir Klaus Hermansen, senior vaccine specialist of NNE Pharmaplan. Dr. Han van den Bosch, professor of Free University, Amsterdam, The Netherlands. Dr. Stanley Chang, CEO of Medigen Biotechnology Corp..
2: Dr. Kathy Tai introduced healthcare information to the public